Perampanel as add-on therapy in epilepsies with known etiology: A single center experience with long-term follow-up.
AE, adverse event
AMPA receptors
ASM, anti-seizure medication
Brain lesion
CTCAE, Common Terminology Criteria for Adverse Events
EEG, electroencephalogram
Efficacy
EiASM, enzyme-inducing anti-seizure medication
ILAE, International League Against Epilepsy
MRI, Magnetic Resonance Imaging
PER, perampanel
Perampanel
Real-world data
Seizures
TLE, temporal lobe epilepsy
Journal
Epilepsy & behavior reports
ISSN: 2589-9864
Titre abrégé: Epilepsy Behav Rep
Pays: United States
ID NLM: 101750909
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
03
2020
revised:
23
09
2020
accepted:
26
09
2020
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
19
1
2021
Statut:
epublish
Résumé
We report a retrospective monocentric study performed on 63 patients affected by epilepsy with known etiology, receiving perampanel as add-on therapy with at least 12-month follow-up. The purpose of our study was to evaluate efficacy and tolerability of perampanel in this group of epilepsies. Patients were classified into 2 groups based on the presence/absence of a single focal brain lesion on MRI, as epilepsy etiology: 48 subjects were affected by focal lesional epilepsy and 15 by non-focal lesional epilepsy. The retention rate was 76.2% and 53.9% at 12 and 24 months respectively. At 12 months, at least 40% of patients resulted responders, with a significant reduction in seizure frequency (
Identifiants
pubmed: 33458643
doi: 10.1016/j.ebr.2020.100393
pii: S2589-9864(20)30041-1
pmc: PMC7797501
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100393Informations de copyright
© 2020 The Author(s).
Références
Expert Opin Pharmacother. 2015;16(15):2355-71
pubmed: 26328621
Lancet. 2006 Apr 1;367(9516):1087-1100
pubmed: 16581409
Epilepsy Behav. 2017 Aug;73:106-110
pubmed: 28624720
Neurology. 2012 May 15;78(20):1548-54
pubmed: 22573629
Epilepsia. 2013 Jan;54(1):117-25
pubmed: 22905857
Neurology. 2015 Sep 15;85(11):950-7
pubmed: 26296511
Epilepsy Curr. 2018 Jul-Aug;18(4 Suppl 1):1-26
pubmed: 30233275
Epilepsia. 2017 Apr;58(4):512-521
pubmed: 28276062
Int J Neurosci. 2019 Jun;129(6):593-597
pubmed: 30507318
Expert Opin Pharmacother. 2017 Nov;18(16):1751-1764
pubmed: 29023170
Epilepsy Behav. 2016 Aug;61:237-241
pubmed: 27393930
Neurology. 2012 May 1;78(18):1408-15
pubmed: 22517103
Epilepsy Res. 2016 Oct;126:201-10
pubmed: 27521586
Neurology. 2012 Aug 7;79(6):589-96
pubmed: 22843280
Epilepsy Res. 2014 Jul;108(5):986-8
pubmed: 24721197
Ther Adv Neurol Disord. 2016 Nov;9(6):445-453
pubmed: 27800020
Epileptic Disord. 2015 Sep;17(3):243-53
pubmed: 26234761
Epilepsia. 1984 Aug;25(4):443-9
pubmed: 6378614
Neurochem Int. 2006 Apr;48(5):394-403
pubmed: 16473439
J Neurol Sci. 2018 Jul 15;390:67-74
pubmed: 29801910
Epilepsia. 2013 May;54 Suppl 2:33-40
pubmed: 23646969